Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban and apixaban are associated with ICH at rates that range from 0.1 to 4% (Agnelli ...
Background: While the effects of stroke can be both debilitating and devastating, the benefit of certain treatments have not always been clear and the data supporting them are fraught with controversy. Reanalysis of the two trials demonstrating the benefit of thrombolytics ...
In this episode of REBEL Cast, Anand Swaminathan and I sit down to discuss the utility of thrombolysis prior to Endovascular therapy for LVO acute ischemic stroke. The discussion is broken up into two potential scenarios: Not all facilities are ...
In this 15-minute lecture from Rebellion in EM 2021, George Willis, MD discusses acute ischemic stroke and the evidence base for and against thrombolysis.
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
